Pulsed Field Ablation Challenges Conventional Devices in AF

In the ADVENT trial, pulsed field ablation, a new technology for terminating drug-refractory paroxysmal AF, was noninferior to conventional thermal ablation but had potential advantages.

Related Keywords

Gentofte ,Hovedstaden ,Denmark ,New York ,United States ,Boston ,Massachusetts ,Copenhagen ,Køavn ,Viveky Reddy ,Biosense Webster ,Arrhythmia Services ,Gentofte University Hospital ,European Society Of Cardiology ,Medtronic ,Boston Scientific ,Cardiac Arrhythmia Services ,Mount Sinai Hospital ,European Society ,New England Journal ,Presented August ,Atrial Fibrillation ,F Atrial Fibrillation ,Tablation ,Catheter Ablation ,Arrhythmia ,Veins ,Esophagus ,Oesophageal ,Nerves ,Refractory ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Cryoablation ,Europe ,European ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,